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CYCLOSPORINE (CyA) has been a major advance in the armamentarium of immunosuppressive agents 
used in clinical transplantation. The use of Cy A and 
steroids has increased patient and graft survival in human 
transplantation. 1,2 Rejection continues to be the most 
common cause of retransplantation, and death is often a 
sequela of treatment of rejection. A number of adverse 
effects of CyA have been well defined; these include 
nephrotoxicity, hypertension, neurotoxicity, hirsuitism, 
and a number of less well-defined side effects. It has been 
suggested that this spectrum of side effects are related to a 
common pathway involving the cyclophyllin receptor. 3 
Alterations in clinical immunosuppression to prevent or 
reverse these and other side effects have included (1) 
reduction of CyA dose or (2) addition of azathioprine, 
antilymphocyte antibodies, or other agents with concomi-
tant reductions in the CyA dose. These methodologies 
have their inherent dangers: increased susceptibility to 
rejection, and increased susceptibility to infection, respec-
tively. 
FK 506 is a potent and novel immunosuppressive agent. 
At the Second International Workshop on FK 506, held in 
Barcelona, Spain in October 1989, an initial report on the 
use of FK 506 for conversion of patients with Cy A failure 
to FK 506 was given. This report included the plan to 
administer FK 506 to 40 patients who were rejecting their 
liver grafts in spite of conventional immunosuppression.4 
The initial protocol was to combine low doses of FK 506 
with CyA, which was attempted in the early experience; 
however, this combination was accompanied by a number 
of adverse reactions. Eventually, a simple switch (clean 
conversion) was made from CyA to FK 506. 
The following is a detailed account of the first 246 liver 
transplant recipients converted from CyA, steroids, and/or 
azathioprine to FK 506 with or without low-dose steroids. 
The results are analyzed by indications for entrance into 
the protocol. 
PATIENTS AND METHODS 
Study Design 
This trial was conducted at the University of Pittsburgh, Presby-
terian-University Hospital, Children's Hospital, and the Veterans 
Administration Medical Center (Pittsburgh, P A), with the ap-
proval of the respective institutional review boards. Informed 
consent was obtained from patients or their appointed guardians. 
The accrual period for this study began on February 28, 1989, and 
continued to May 31, 1990. A minimum follow-up period of 2 
months was obtained on all patients. The median follow-up period 
was 240 days. 
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Patient Profiles 
Two hundred forty-six patients were entered in the study. During 
this period, 15 other patients were converted to FK 506 from CyA 
at the time of retransplantation, and these results have been 
reported elsewhere.s Of the 246 patients converted to FK 506, 27 
patients received their liver allografts at centers other than the 
University of Pittsburgh, but were subsequently accepted for FK 
506 therapy. 
Most of the 246 patients were bearing their first liver allograft at 
the time of the conversion from Cy A to FK 506. A smaller number 
of patients had previously undergone more than one previous liver 
transplant. One patient was carrying his fifth liver transplant at the 
time of FK 506 conversion (Table I). 
The median time from transplantation to FK 506 conversion 
was 19 months (range, 0.1 to 78 months). The clinical profiles of 
the patients are shown in Table I. The median age was 42 years 
(range, 1 to 66 years). The sex distribution of the 246 patients was 
124 males and 122 females. 
Indications 
The original diagnoses of the 246 patients are shown in Table I. 
Most of the patients had cryptogenic cirrhosis or post necrotic 
cirrhosis due to non-A, non-B hepatitis. Cholestatic cirrhosis and 
alcoholic cirrhosis made up the major remainder of indications. 
All patients switched to FK 506-based immunosuppression had 
an entry diagnosis of liver allograft dysfunction andlor other 
complications related to CyA, ie, renal dysfunction, hypertension, 
severe neurotoxicity, or complications related to severe steroid 
toxicity. Cyclosporine-related complications were defined as renal 
failure (a serum creatinine >2.0 mg/dL) andlor postoperative 
hypertension (diastolic blood pressure> I 00 despite antihyperten-
sive medications). Steroid toxicity was defined as steroid-induced 
osteoporosis resulting in multiple bony fractures or morbid obe-
sity. Prior to conversion to FK 506, maintenance immunosuppres-
sion in all patients was with CyA and prednisone, with or without 
azathioprine. Cyclosporine doses had been maximized to tolera-
ble levels, as limited by renal dysfunction or hypertension. 
Seventy percent of the patients had received at least one course of 
OKT3 prior to conversion to FK 506. These patients were, 
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Table 1. Clinical Profile of FK 506 Conversion Patients 
Median age (y): 42 
Sex (M/F): 124/122 
Liver allograft treated 
No.1: 203 
No.2: 
No.3: 
NO.4: 
No.5: 
Original diagnosis 
Cryptogenic cirrhosis: 
Laennec's cirrhosis: 
Primary biliary cirrhosis: 
Sclerosing cholangitis: 
Hepatitis B: 
Biliary atresia: 
Autoimmune cirrhosis: 
Malignancies: 
Miscellaneous: 
Indications for FK 506 
Acute rejection: 
Acute rejection/hepatitis: 
Chronic rejection: 
Chronic rejection/hepatitis: 
Hepatitis: 
Non-hepatic indications: 
Steroid toxicity: 
Renal failure: 
Hypertension: 
Neurotoxicity: 
Multiorgan system failure: 
32 
9 
79 
34 
32 
25 
14 
13 
10 
10 
39 
64 
8 
113 
18 
11 
7 
14 
3 
2 
6 
therefore, considered treatment failures of conventional immuno-
suppression. 
The indications for FK 506 conversion are shown in Table 1. In 
several instances, more than one coexistent indication was 
present. When possible, the indication that most severely affected 
the patient was used to classify the patient. Rejection was the 
indication for treatment in 177 patients. Acute rejection was seen 
in 64 allografts (referred to as "acute rejection"). Chronic rejec-
tion was seen in 113 allografts (referred to as "chronic rejection "). 
A predominantly hepatitic component was seen in 11 patients 
(referred to as "hepatitis"). Coexistent hepatitis was seen in 
another 26 patients who also had an element of rejection (eight for 
"acute rejection/hepatitis" and 18 for "chronic rejectionlhepati-
tis"). Twenty-six liver allograft recipients were converted to FK 
506 in the attempt to control the side effects of CyA and steroid 
therapy (referred to as "nonhepatic indications"). Fourteen of 
these patients were converted purely for renal failure, seven 
patients were converted for severe steroid-associated complica-
tions, three patients were converted for refractory hypertension 
related to CyA, and two patients were converted for severe 
neurotoxicity. 
Diagnostic Evaluations 
The indications for conversion were based on clinical, biochemi-
cal, and histopathologic diagnoses. The cause of liver dysfunction 
was carefully evaluated prior to enrollment in the study. Ultra-
sonic determination of vessel patency and radiographic evaluation 
of the biliary system were used to rule out a technical or 
mechanical defect. Angiography was performed when indicated. 
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Biopsies were performed at the initiation of FK 506 therapy, 
and at 2 months following FK 506 conversion. Liver biopsies were 
performed in all but 10 patients prior to entry. Six patients had 
markedly abnormal coagulation parameters, making a liver biopsy 
unsafe. Four patients did not undergo biopsy, their entrance 
criterion being steroid toxicity. An important criterion for entry 
was the blinded pathologic interpretation of the liver biopsy by a 
single experienced liver pathologist (A.J.D.). Biopsy specimens 
were fixed in neutral-buffered formalin and routinely stained with 
hematoxylin and eosin, trichrome, and reticulin stains. 
The following histologic criteria were used for the pathologic 
diagnosis of acute hepatic rejection: 
1. A predominantly mononuclear portal tract infiltrate in which 
the inflammatory infiltrate consisted of 50% to 60% mono-
nuclear cells intermixed with polymorphonuclear cells and 
eosinophils. 
2. Characteristic localization of the inflammatory cells around 
and beneath the swollen endothelium of portal capillaries 
and small veins, with infiltration and damage of the epithe-
lium of small bile ductules. The number of damaged bile 
ductules and the degree of damage generally increased with 
time. The most severe changes, with ductular loss, were 
seen in chronic rejection. 
3. Absence of histologic findings suggestive of hepatitis. 
A diagnosis of chronic hepatic rejection was made if there was 
evidence of the following: 
1. the obliterative arteriolar lesions that have been found in the 
liver as well as other solid organs,I.6 
2. loss of intrahepatic bile ducts, often with only a mild 
periductal and intraductal chronic inflammatory infiltrate, 
3. portal fibrosis, especially if linkage had occurred between 
portal tracts or central veins, and 
4. absence of lobular changes suggesting hepatitis. 
A diagnosis of hepatitis was made if there was evidence of 
1. Significant panlobular inflammation, piecemeal necrosis, 
cholangiolar proliferation, disarray with ballooning and 
spotty individual hepatocyte necrosis, and prominent Iym-
phohistiocytic infiltration of the hepatic lobule with inflam-
matory cell destruction of hepatocytes. The foregoing are 
not prominent features of rejection under immunosuppres-
sion and suggest a diagnosis of viral hepatitis. 
2. Positive staining for viral proteins, or positive growth of 
virus from liver biopsy specimens. In one patient, an incor-
rect initial diagnosis of acute cellular rejection was modified 
to acute hepatitis B infection after special staining of the liver 
biopsy for hepatitis B core and surface antigen appeared 
positive 3 days following initiation of FK 506 treatment. 
Treatment with FK 506 was stopped. 
When it was the clinician's opinion that the biopsy reading 
underestimated the severity of the rejection episode, the criteria 
for rescue therapy was based primarily on biochemical and 
clinical parameters, such as elevations of serum transaminases or 
serum bilirubin to greater than 50% of baseline, clinical signs, 
such as fever, and changes in bile characteristics in those who had 
T-tubes. 
Timing and Details of Therapy 
Cyclosporine was discontinued 24 hours prior to the initiation of 
FK 506 therapy. Initiation of treatment with FK 506 was done in 
the hospital and was administered initially as a parenteral dose, 
followed by conversion to an oral dose. The initial parenteral dose 
of FK 506 was 0.075 to 0.15 mg/kg, administered intravenously 
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over a period of 4 hours. Generally, oral dosages of FK 506 were 
administered at 0.30 mg/kg in divided doses. Dose adjustments of 
FK 506 were based on monitoring of serum trough levels by 
enzyme-linked immunosorbent assay,7 and also by adjustment 
according to clinical or biochemical parameters. As was previ-
ously described, the protocol for conversion from CyA to FK 506 
was different for the first 11 patients, after which time a clean 
conversion was performed for the remaining FK 506 conversion 
patients.4 The majority of the patients remained in the hospital for 
6 days or less following initiation of FK 506, and were followed 
thereafter on an outpatient basis. 
Statistical Analysis 
Comparisons of the liver function tests were analyzed using a 
two-tailed Student's (-test with unequal variances. Probability 
values < .05 were considered statistically significant. All mean 
values are expressed as mean value ± standard error of mean. 
RESULTS 
Patient Survival 
In this population of 246 patients in which many of the 
patients were critically ill at the time of FK 506 conver-
sion, 31 deaths were encountered (12.6%) (Table 2). These 
deaths occurred an average of 74.3 days following FK 506 
conversion. The causes of death were numerous, but the 
incidence of mortality was directly correlated with the 
medical condition of the patient at the time of FK 506 
conversion. Five of the 31 deaths occurred in the 25 
patients who underwent retransplantation. 
When the mortalities were correlated with the indica-
tions for entrance, the highest mortality (six of six) was 
seen in those patients with pre-existing multi organ system 
failure related to sepsis. Of the 37 patients in whom 
significant hepatitis was seen on the pre-FK 506 biopsy, 
seven deaths (19%) were noted. Twelve (11%) of the 113 
patients with chronic rejection died during this period. 
Only five of the 64 patients (8%) with acute rejection died. 
while the 26 patients with no evidence of liver dysfunction 
had the lowest mortality rate, with only two patients (7%) 
dying in the follow-up period. 
Sepsis was the cause of death in 13 patients. Of these, 
Table 2. Causes of Graft and Patient Loss 
Patient loss 
Liver failu re 
Non A-Non B hepatitis: 
Fulminant hepatitis B: 
Non-retransplantable: 
Metastatic carcinoma: 
Sepsis: 
Renal failure: 
Hemorrhage: 
Operative death: 
Unknown causes: 
Graft loss 
Chronic rejection: 
Hepatic artery thrombosis: 
Hepatitis: 
3 
4 
3 
13 
1 
3 
2 
15 
3 
7 
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six were overtly septic at the time ofFK 506 rescue. Each 
of these patients succumbed to mUltiple organ failure from 
sepsis an average of 13 days after institution of FK 506 
therapy (range, 3 to 31 days). These patients were catego-
rized as "multisystem organ failure" because of multisys-
tem failure secondary to sepsis. In five patients, the causes 
of sepsis after FK 506 conversion were cytomegalovirus 
pneumonia (one patient), candida pneumonia (one), can-
dida peritonitis following bile duct reconstruction (one), 
bacterial pneumonia (one), and hemorrhagic pancreatic 
abscess in a patient with recurrent pancreatitis (one). The 
final two deaths were in two patients who underwent 
retransplantation; one developed an aspiration pneumonia 
and the other developed intra-abdominal sepsis. 
In one patient, hepatic failure from hepatitis B was the 
cause of death. The original disease was not related to 
hepatitis B, and conversion to FK 506 was performed 
because of suspected rejection. The original diagnosis was 
incorrect, a fact that was only determined 3 days after FK 
506 was started. The patient was taken off FK 506 and 
emergent retransplantation was performed, but she died 2 
days later from suppurative bacterial pneumonia. 
Three patients died of metastatic carcinoma. In each of 
these patients, the metastatic lesions were identical histo-
logically with the tumor removed at the time of transplan-
tation. These deaths occurred at 1, 2.5, and 6 months 
following FK 506 conversion, and 1,3.5, and 6.5 months 
after transplantation. 
In four patients, retransplantation was not considered an 
option for the failing liver allograft. Two patients had 
prolonged liver dysfunction with evidence of chronic re-
jection, while one had a larger component of biliary 
stricturing. One patient had intra-abdominal sepsis and 
required emergent ligation of the hepatic artery. FK 506 
was offered as a rescue option, although it was felt that the 
possibility of success was remote. These four patients died 
15.32,81, and 137 days after FK 506 was started. 
Three patients died from liver failure related to recurrent 
non-A, non-B hepatitis. All three patients developed re-
current non-A, non-B hepatitis and were converted to FK 
506. The liver dysfunction progressed in all cases, and, in 
one case, retransplantation was attempted. The new liver 
developed recurrent non-A, non-B hepatitis, and this pa-
tient died of liver failure. 
Three patients died of hemorrhagic complications. In 
one patient, a rupture of a mycotic pseudoaneurysm 
required ligation of the celiac axis which was complicated 
by renal failure 9 months following transplantation. The 
patient was converted to FK 506 and eventually recovered 
normal renal function. Two months later, a recurrent 
intra-abdominal hemorrhage occurred from a mycotic an-
eurysm that formed at the aortic orifice. leading to the 
patient's death. In another patient, an unsuspected splenic 
artery aneurysm ruptured 3 days after FK 506 conversion. 
The patient could not be resuscitated. The third patient 
died after sustaining a lacerated subclavian artery during 
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an attempt to place a central venous line, causing a 
massive hemothorax and uncontrollable bleeding. 
One patient was started on FK S06 with pathologic 
findings of late chronic rejection. These changes could not 
be reversed with FK S06. The patient died of technical 
causes during an attempted retransplantation. 
In two deaths, no clear cause of death could be deter-
mined. Both of these patients died at home. One patient 
had been off FK S06 for 4 months at the time of death. 
Finally, a complex patient with scleroderma and autoim-
mune hepatitis developed renal failure after transplanta-
tion. FK S06 was started 3 months after the original 
transplant in hopes of reversing the renal failure. The 
patient refused further dialysis after 4 months on FK S06, 
which was discontinued, resulting in the patient's death. 
Graft Survival 
Of the 246 liver allografts analyzed, SI grafts were lost 
from either retransplantation or patient death. This left 196 
liver allografts currently functioning. The causes of graft 
loss are listed in Table 2. Twenty-five grafts failed, requir-
ing retransplantation. Fifteen liver allografts were lost to 
chronic rejection, unresponsive to FK S06 therapy. Three 
grafts were lost to hepatic artery thrombosis, and seven 
were lost to progressive hepatitis affecting the liver al-
lograft. These graft losses occurred a mean of 76.2 days 
after FK S06 conversion. 
When the causes of retransplantation were correlated 
with the indications for entrance, the highest rate was seen 
in those patients with pre-existing hepatitis. Of the 37 
patients in whom significant hepatitis was seen in the 
pre-FK S06 biopsy specimen, retransplantation was re-
quired in seven (19%). Fourteen of the 113 patients (12%) 
with chronic rejection required retransplantation during 
this period. Only three of the 64 patients (S%) with acute 
rejection required retransplantation, while none of the 26 
patients without evidence of liver dysfunction did so. 
Biochemical Response of the Liver Allograft 
The biochemical response of the liver allografts to FK S06 
was broken down into the specific indications for which 
the patients were switched to FK S06. 
Fig 1 shows the total bilirubin and transaminase levels 
for the 64 patients who were treated for acute rejection, 
documented on liver biopsy or as judged by biochemical 
and clinical parameters (acute rejection). The total biliru-
bin (TBlL), serum glutamic-oxaloacetic (SGOT), and se-
rum glutamate pyruvate transaminase (SGPT) prior to FK 
S06 were 4.96 ± 0.81 mgldL, 207 ± SI lUlL, and 281 ± 47 
lUlL, respectively. These values fell, by the sixth month, 
to 0.46 ± 0.04 mgldL, 52 ± 6.5 lUlL, and S4 ± 7.S lUlL, 
respectively. 
Patients with an entrance diagnosis of chronic rejection 
also had a beneficial response to FK S06. Fig 2 shows the 
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Fig 1. Improvement in liver function studies in patients with 
chronic rejection who have been switched to FK 506. 
total bilirubin and transaminase levels for the 113 patients 
treated for this specific indication (chronic rejection). 
While the total bilirubin fell to normal values (pre-FK S06, 
S.08 ± 0.74 mgldL; 6 months later, 0.81 ± 0.12 mgldL) , the 
average transaminase values were still slightly elevated 
above normal values (pre-FK 506, SGOT/SGPT, 198 ± 
17.1 IU/Ll271 ± 2.7 lUlL; 6 months later, SGOT/SGPT, 69 
± 6.4 IU/Ll84.S ± 11.0 lUlL). 
Of interest is a subgroup of FK S06 conversion patients 
with chronic rejection occurring more than 90 days after 
trarisplantation, with an entrance total bilirubin of more 
than 2.S mg/dL. These parameters define a subgroup of 
patients with chronic rejection who have done poorly in 
the past. Fig 3 shows the response of these patients to FK 
S06. A total of 40 patients were categorized into this 
subgroup, of which 11 required retransplantation, 10 for 
persistent chronic rejection and one for hepatic artery 
thrombosis. Five patients died. This left 24 patients with 
functioning liver allografts. When this group of 24 patients 
with functioning chronic rejecting liver allografts were 
analyzed for their response to FK S06 conversion, it was 
evident that this group responded favorably. There was a 
highly significant statistical decline in all liver functions. 
The mean values were lower at all time points when 
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Fig 2. Treatment response of chronically rejecting, end-stage 
liver allografts with FK 506. 
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Fig 3. Influence of pre-existing hepatitis in the response of liver 
allografts to conversion to FK 506. 
compared with the baseline values (pre-FK 506: TElL, 
7.52 ± 1.23 mg/dL; SOOT, 280 ± 47.6 lUlL; SOPT, 401 ± 
97.1 lUlL; 6 months later: TBIL, 1.07 ± 0.38 mg/dL; 
SOOT, 96.3 ± 19.5 lUlL; SOPT, III ± 24.8 lUlL). 
Patients who had indications for FK 506 conversion not 
related to liver allograft dysfunction were categorized as 
non-hepatic indications. A total of26 patients were treated 
for steroid toxicity (seven patients), renal failure (14), 
refractory hypertension (three), and neurotoxicity (two). 
The liver functions remained normal throughout the fol-
low-up period in this subset of patients who were con-
verted for indications other than liver dysfunction (data 
not shown). 
In a group of patients in whom hepatitis was the sole or 
a major coexistent process prior to FK 506 conversion, the 
liver function studies were analyzed. As previously men-
tioned, 12 of the 37 grafts were lost either to retransplan-
tation or to patient death. Hepatitis was a factor in this loss 
in 10 of the 12 grafts. Of the remaining 25 liver allografts 
available for analysis, there was less appreciable effect of 
FK 506 on liver function. As shown in Fig 4, the response 
of grafts with hepatitis was not as dramatic as that seen 
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Fig 4. Examples of recovery of end-stage liver disease in two 
patients with chronic graft-versus-host disease following bone 
marrow transplantation. 
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with dysfunctional grafts due to rejection alone. There was 
an initial, statistically significant, improvement in the trans-
aminases by the second month (SOOT: pre-FK 506, 156 ± 
24.5 lUlL; 2 months later, 94.7 ± 11 lUlL; SOPT: pre-FK 
506,270 ± 41.8 lUlL; 2 months later, 130 ± 16 lUlL). This 
may have reflected improvement in the rejection process, 
which was a component in 15 of the 25 livers analyzed. By 
the sixth month, there was gradual deterioration in the 
transaminases such that the SOOT rose to 135 ± 38.8 lUlL 
and the SOPT rose to 134 ± 28.5 lUlL. In general, this rise 
was correlated to increased hepatocellular disarray. 
Histologic Response of the Liver Allograft 
In each case in which histopathologic changes were pre-
dominant, the influence of FK 506 on the initial findings of 
rejection or hepatitis could be evaluated in serial follow-up 
biopsies. Overall, 17% of the biopsy specimens with a 
diagnosis of rejection showed worsening of the pathology. 
Thirty-six percent of the liver biopsy specimens showed no 
pathologic changes between the pre-FK 506 biopsy and the 
2-month follow-up biopsy. Forty-seven percent of the 
remaining biopsy specimens showed improvement be-
tween the initial and the follow-up biopsies. These changes 
were particularly impressive in patients whose pretreat-
ment biopsy specimens contained bile duct lesions that 
generally progress to bile duct disappearance and graft 
loss, in spite of intensive immunosuppression. In those 
liver allografts in which hepatitis was a predominant find-
ing in the pre-FK 506 conversion biopsy, 50% of the 
follow-up biopsy specimens showed worsening of the 
hepatitic picture. 
Renal Function 
On the whole, renal function, as assessed by serum blood 
urea nitrogen (BUN) and creatinine (Cr), rose during the 
first few weeks after FK 506 conversion. These values 
gradually fell during the ensuing follow-up period. The 
pretreatment BUN and Cr were 37.1 ± 1.47 mg/dL and 
1.78 ± 0.11 mg/dL, respectively. These values peaked at 
39.7 ± 1.46 mg/dL and 2.27 ± 1.02 mg/dL, respectively, 
before declining to 31.6 ± 2.01 mg/dL and 2.01 ± 0.20 
mg/dL, respectively, by the sixth month. 
Pre-existing renal dysfunction was noted in 24.8% of the 
patients, due to primary kidney disease or Cy A. Two of 
these patients had previously undergone cadaveric renal 
transplantation with dysfunction of the kidney allograft. In 
the 244 patients with native kidneys, 59 patients had renal 
failure as defined by a serum creatinine greater than 2 
mgldL (50 of 244), or the requirement for hemodialysis 
(nine of 244). Because of the heterogeneity of the kidneys 
being studied and the confounding factor of prior treatment 
with Cy A, the nephrotoxicity of FK 506 could not be 
accurately ascertained. Three of the nine patients on 
hemodialysis have actually recovered renal function while 
on FK 506 and do not require further hemodialysis. 
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Side Effect 
Insomnia 
Tremors 
Headache 
Hyperesthesia 
Musculoskeletal 
Blurred vision 
Itching 
Fatigue 
Gas pain 
Table 3. Incidence of Side Effects· 
Hair loss 
Photophobia 
Decreased appetite 
Diarrhea 
Nausea 
Increased appetite 
Sweating 
Tinnitus 
Dizziness 
Nightmares 
Hair growth 
Chest Pain 
Incidence 
(%) 
31 
26 
22 
21 
20 
19 
18 
17 
17 
16 
15 
14 
12 
10 
10 
9 
9 
7 
7 
6 
3 
a Represents a cumulative frequency based on 1,515 patient interviews. 
In the subgroup of patients with pre-existing renal failure 
as the sole indication for FK 506 conversion, the BUN and 
Cr values prior to FK 506 were 46.9 ± 4,3 mg/dL and 3.11 
± 0.19 mg/dL, respectively, Renal function improved in 
this group of patients and, at the end of6 months, the BUN 
and Cr values were 32.5 ± 5.8 mg/dL and 2.33 ± 0.24 
mg/dL, respectively (data not shown). 
In six patients who had either poor renal function or who 
were on hemodialysis at the onset of FK 506 therapy. 
cadaveric renal transplantation was undertaken during the 
course of FK 506 therapy for persistent renal failure. Two 
kidney allografts failed; one was from a patient who 
required an allograft nephrectomy 1 month following kid-
ney transplantation for a mycotic aneurysm. The recipient 
(who was on CyA) receiving the mate kidney also hemor-
rhaged from a mycotic aneurysm. The second patient was 
a sensitized recipient and received a kidney that never 
functioned. He remains dialysis-dependent. In the remain-
ing four patients, with a mean follow-up of 11 months, 
renal function remains excellent, with the average serum 
creatinine being 1.2 mg/dL (range, 0.7 to 1.8 mg/dL). 
Adverse Reactions 
A detailed questioning of patients was performed for all 
patients converted to FK 506 from CyA. The overall 
incidences of side effects from FK 506 given to this group 
of patients are listed in Table 3. The most common side 
effect of FK 506 administration was insomnia, occurring in 
31 % of all patients at some time after FK 506 conversion. 
This was followed by tremors, primarily in the upper 
extremities, which were seen in 26% of the patients. 
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Headaches occurred in 22% of the patients. Hyperesthe-
sias of the feet were noted in 21% of the patients. Photo-
phobia was seen in 15% of all questionnaires. 
FK 506 therapy was also associated with a number of 
transient gastrointestinal complaints. Ten percent of the 
patients noted nausea or vomiting, 12% noted diarrhea, 
10% noted increased appetite, and 14% noted decreased 
appetite. Gas pains were reported in 17% of the patients. 
Hyperkalemia was seen in 35% of patients following 
administration of FK 506. Treatment was initiated with 
potassium-binding resins and potassium-restricted diets. 
Addition of a synthetic mineralocorticoid, Florinef, re-
lieved the hyperkalemia in all of these patients. 
One case of Iymphoproliferative disease was found in 
this group of patients. This was seen in a 5-year-old girl 
with an original diagnosis of biliary atresia. She received 
one course of OKT3 during the second posttransplant 
week. She had persistent rejection and was converted to 
FK 506 1 month following transplantation. She did well 
until an episode of gastrointestinal bleeding was noted 7 
months after FK 506. Upper endoscopy revealed a gastric 
ulcer that was interpreted as showing a polyclonal lym-
phoma of the stomach. Treatment consisted of the admin-
istration of intravenous acyclovir and the lowering of FK 
506 doses. A repeat endoscopy 1 month later revealed 
healing of the ulcer. 
DISCUSSION 
This report confirms our initial report4 on the usefulness of 
FK 506 conversion for patients with refractory complica-
tions due to Cy A, including rejection, hypertension, neph-
rotoxicity, and steroid toxicity. However, we have also 
defined circumstances in which FK 506 conversion is not 
beneficial and, perhaps, deleterious. 
In the high-risk group of patients with chronic rejection, 
many of whom had received previous azathioprine, OKT3, 
and/or high doses of steroids, over 70% of the patients 
treated by conversion to FK 506 had both clinical and 
histopathologic responses. Marked improvement in bio-
chemical parameters was noted in a majority of patients 
whose values were abnormal prior to conversion to FK 
506. Even with a group of patients with end-stage liver 
disease from chronic rejection with marked liver function 
abnormalities, liver functions responded favorably. This 
phenomenon, not seen before with patients on CyA, 
OKT3, or azathioprine, may be related to a hepatotrophic 
effect of FK 506 on the liver. 8 ,9 Unlike CyA, which also 
possesses hepatotrophic qualities in the liver,9 FK 506 is 
able to reverse the pathologic findings of chronic rejection, 
including small bile ductular damage and 10ss.IO The limi-
tation in the ability to rescue a chronically rejecting liver 
allograft is likely to be the arterial inflow and the require-
ment for some residuum of portal biliary structures. Those 
patients with a diagnosis of chronic rejection who did not 
respond to FK 506 conversion had histopathologic evi-
dence of end-stage chronic rejection with obliteration of 
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the vascular lumen and total disappearance of intrahepatic 
bile duct structures. 
FK 506 has been shown to reverse ongoing acute 
cellular rejection in animal models when started early in 
the rejection episode. 11 This study demonstrates a marked 
ability of FK 506 to reverse ongoing acute cellular rejec-
tion. Liver functions stabilize and revert toward normal, 
usually within several days of starting FK 506. The quality 
of dose adjustability in the treatment of rejection has 
always been considered to be limited to steroids. The 
consideration that an agent which, theoretically, acts in a 
manner similar to Cy A (but is able to reverse ongoing 
rejection) will force those studying transplant immunobiol-
ogy to re-examine the effect of FK 506 on the immune 
response. It should be suspected that the biologic effect 
that FK 506 is able to achieve is more than merely affecting 
the genesis of rejection. This phenomenon may account 
for the successful use of FK 506 in primary liver transplan-
tation, and the low rates of rejection seen in those 
patients. 5 
Patients with hypertension, nephrotoxicity, steroid tox-
icity. or neurotoxicity have responded to FK 506 conver-
sion. All patients with steroid toxicity were able to stop 
steroids. The number of patients treated for the indications 
of hypertension or neurotoxicity are too small to make a 
generalization; however, conversion to FK 506 affords 
maintenance of adequate immunosuppression. Some pa-
tients with nephrotoxicity related to Cy A have also bene-
fited from FK 506. However, we have not yet been able to 
prospectively identify those patients in whom this conver-
sion will fail. 
FK 506 is remarkably well tolerated. Yet, FK 506 and 
CyA share many similar biologic properties. Both immu-
nosuppressive agents have specificity toward T cells. Both 
drugs inhibit interleukin-2 synthesis and, therefore. T-cell 
proliferation. 12. 13 The mechanism whereby these drugs 
inhibit T cell function is thought to be in an inhibition of 
their respective receptors, which are peptidyl-prolyl cis-
trans isomerases, 14.15 and is considered to be important in 
a number of protein-folding events. 16 While some of the 
neurotoxicity, nephrotoxicity, and diabetogenic effects of 
both drugs are similar, there are marked differences. The 
incidence of hypertension is less, while gingival hyperpla-
sia and hirsuitism is virtually nonexistent. 
While it is tempting to speculate on the possible role of 
FK 506 on reparative processes following control of rejec-
tion, further investigations in this area are necessary. Of 
special interest is the possibility of using FK 506 in disease 
processes in which biliary structures are targets of immune 
destruction. Two patients have been treated with FK 506 
for control of chronic graft-versus-host disease following 
bone marrow transplantation. Both patients manifested 
liver disease related to destruction of the portal biliary 
structures, similar to that seen in chronic liver allograft 
rejection. Indeed, both histologically and immunopatho-
logically, the mechanism of liver injury is similar in both 
disease processes. Both patients have had dramatic re-
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Fig 5. Improvement in liver function studies in patients with 
chronic rejection who have been switched to FK 506. 
sponses to FK 506. The serum bilirubin profiles in the 
patients treated are shown in Fig 5. The canalicular en-
zymes have also shown a marked response to FK 506 (data 
not shown). It will be of great interest to determine the 
possibility of rescuing failing livers in patients with chronic 
graft-versus-host disease. 
The ultimate role of FK 506 in the treatment of immune-
regulated diseases is not clear; however, the ability of FK 
506 to affect diverse target systems will make it attractive 
to study. 
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